A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
> IL-6 and IL-6 Receptor Proteins 
In 1973, Interleukin 6 (IL-6) was identified as a soluble factor secreted by T cells, which is essential for the production of antibodies by B cells. Since its discovery nearly 50 years ago, the IL-6 signaling pathway has emerged as a key pathway involved in immune regulation in health and immune dysregulation in many diseases.
In the classical pathway, IL-6 binds to both transmembrane and soluble forms of its receptor IL-6 R，namely mIL-6R and sIL-6R. After that, the complex binds to the Glycoprotein 130（gp130） and downstream signaling and gene expression are triggered. In the trans- signaling pathway, the complex of sIL-6 with the receptor binds to gp130, and intracellular signal transduction is initiated. In the next step, the JAK-STAT, RAS-RAF, and other pathways are activated, promoting cellular proliferation, differentiation, oxidative stress, and immune regulation. The classical IL-6 signal is limited to the cells (macrophages, neutrophils, T cells, etc.) that express IL-6R. But when IL-6 levels are elevated, the signal is widely expressed due to the ubiquitous nature of gp130.
IL-6 signaling pathwayFurthermore, emerging evidence suggests that dysregulation of IL-6 contributes to a variety of disease states, including various types of cancer development, progression, and metastasis, increased levels of IL-6 are associated with a higher risk of cancer and other diseases, such as insulin resistance, asthma, coronary heart disease, advanced cancer, and can also serve as a prognostic marker for cancer. Targeting this pathway may expand to the treatment of several other symptoms, such as uveitis, neuromyelitis optica, and more recently, COVID-19 pneumonia.
ACROBiosystems has developed a series of high-quality IL-6 and IL-6 receptor proteins to facilitate the development of IL-6 related drugs.
Human and Mouse species are available
High purity：＞95%
High bioactivity verified by ELISA, BLI and cell-based assay. Free protocols offered
Various tags：Tag Free，His Tag，Avi & His Tag，Fc Tag
Low endotoxin：＜ 1.0 EU/μg
| Molecule | Cat. No. | Species | Product Description | Preorder/Order |
|---|---|---|---|---|
| IL-6 | IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |
|
| IL-6 | IL6-H4218 | Human | ActiveMax® Human IL-6 Protein, Tag Free |
|
| IL-6 | IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |
|
| IL-6 | IL6-M82Q7 | Mouse | Biotinylated Mouse IL-6 Protein, Avitag™,His Tag |
|
| IL-6 | IL6-C5249 | Cynomolgus | Cynomolgus IL-6 Protein, His Tag (MALS verified) |
|
| IL-6 R alpha | ILR-H4223 | Human | Human IL-6 R alpha / CD126 Protein, His Tag |
|
| IL-6 R alpha | CD6-H82E8 | Human | Biotinylated Human IL-6 R alpha / CD126 Protein, Avitag™,His Tag |
|
| IL-6 R alpha | ILR-H5259 | Human | Human IL-6 R alpha / CD126 Protein, Fc Tag |
|
| IL-6 R alpha | ILR-M82E9 | Mouse | Biotinylated Mouse IL-6 R alpha / CD126 Protein, His,Avitag™ |
|
| gp130 | ILT-M52H1 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, His Tag |
|
| gp130 | ILT-M5252 | Mouse | Mouse gp130 / CD130 / IL-6 R beta Protein, Fc Tag |
|
Biotinylated Human IL-6 R alpha, Avitag, His Tag (Cat. No. CD6-H82E8) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%. The protein has a calculated MW of 41.7 kDa and migrates as 55-70 kDa due to glycosylation.
ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL.
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL.
＞＞【Inspiring Target】Therapeutic potential of IL-6 immunization in multiple fields continues to burst
Authors:Choy, E.H., De Benedetti, F., Takeuchi, T. et al.
Authors:Atal, S., Fatima, Z.
Authors:Anjali Dhall et al.
Authors: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
Authors:Fu, B., Xu, X. & Wei, H.
This web search service is supported by Google Inc.
